Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 24, 2026.

Understanding Keloid Pathobiology From a Quasi-Neoplastic Perspective: Less of a Scar and More of a Chronic Inflammatory Disease With Cancer-Like Tendencies

Silvian Tan, Nonhlanhla Khumalo, Ardeshir Bayat

Frontiers in Immunology · 2019 · Review · CC BY

doi:10.3389/fimmu.2019.01810

Abstract

Keloids are considered as benign fibroproliferative skin tumors growing beyond the site of the original dermal injury. Although traditionally viewed as a form of skin scarring, keloids display many cancer-like characteristics such as progressive uncontrolled growth, lack of spontaneous regression and extremely high rates of recurrence. Phenotypically, keloids are consistent with non-malignant dermal tumors that are due to the excessive overproduction of collagen which never metastasize. Within the remit of keloid pathobiology, there is increasing evidence for the various interplay of neoplastic-promoting and suppressing factors, which may explain its aggressive clinical behavior. Amongst the most compelling parallels between keloids and cancer are their shared cellular bioenergetics, epigenetic methylation profiles and epithelial-to-mesenchymal transition amongst other disease biological (genotypic and phenotypic) behaviors. This review explores the quasi-neoplastic or cancer-like properties of keloids and highlights areas for future study.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 24, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Keloids are considered as benign fibroproliferative dermal tumors, which are borne out of abnormal wound healing processes following injury to the skin. They are characterized visually by raised exophytic dermal outgrowths extending beyond the original wound boundary and microscopically by thickened hyalinized collagen bundles.

Most individuals affected by keloid disease are aged between 10 and 30 years and are of pigmented skin with high reports in African, Afro-Caribbean, Afro-American, Hispanic, or Asian ancestry. Keloids may develop months or years after the initial injury and can be accompanied by intense pain, pruritus, and other physical, and psychosocial symptoms. Common sites affected are the anterior chest, shoulders, back, and earlobe, with those on the pre-sternum and shoulder regions developing under high tension. Keloids tend to be aggressive in invading adjacent surrounding healthy (normal) skin and can often recur following any form of treatment. In particular, monotherapy with surgical removal alone carries a recurrence rate of up to 100%. Phenotypically, keloids are consistent with non-malignant dermal tumors that are due to the excessive overproduction of collagen which never metastasize. However, the morphology and clinically aggressive behavior of keloids can be thought to bear a resemblance to neoplastic dermal tumors.

Different theories exist to explain the etiology of keloids, including elevated skin tension, hypoxia, chronic inflammation, autoimmune, genetics, and vascular factors, none of which, however, are independently sufficient to do so. To date, options for keloid treatment are poorly defined, in part due to unsatisfactory outcomes of current treatments and the poor quality of evidence surrounding their use. Compounding keloid research is the lack of animal disease models for testing.

This review aims to explore the salient cancer-like or quasi-neoplastic attributes and features of keloids (Figure 1) and highlights several key areas for future study.

Keloids: Scars or Cancerous Tumors?

Keloids are traditionally viewed as scars on the spectrum of fibroproliferative dermal diseases. To elucidate the etiopathogenesis of keloids, however, the distinction between scar and disease must be made. A scar is the endpoint of physiological wound healing, preceded by inflammation, fibroplasia and granulation, and manifest as non-functioning fibrotic tissue, which may regress over time. Cutaneous scars often undergo changes in properties such as thickness, texture, color, and strength but remain within the confines of the surrounding intact skin. In contrast, keloids are aggressive exophytic dermal outgrowths disproportionately grown beyond the boundaries of the original wound, from a source, which remains suspended in “wound healing” and scar maturation. Although keloids are not routinely classified as true neoplasms due to their lack of spontaneous occurrence and absence of metastasis, they exhibit various cancer-like characteristics such as uncontrolled proliferation, invasiveness into surrounding tissue, lack of spontaneous regression and ability to vascularize. Their disproportionately locally aggressive clinical phenotype suggests possible links with skin or mesenchymal tumors that need to be explored in further detail.

Owing to their similar clinical presentation, keloids have been misdiagnosed as other benign and malignant skin tumors and vice versa. Of these, dermatofibrosarcoma protuberans is the most commonly linked to keloids amongst others such as keloidal dermatofibroma, keloidal basal cell carcinoma, keloidal atypical fibroxanthoma, suggesting a possible overlap between them. Based on their pathobiology and clinical phenotype, keloids bear the most similarity between tumors relating to fibrosis, dermal origin, and mesenchymal origin. Similarities between keloids and mesenchymal tumors can be found across a range of characteristics from biomarker expression to clinical presentation. Seminal work on keloid mesenchymal-related biomarkers suggests that stem-cell like cells identified in keloids deviate from dermal to chondrocytic or osteogenic lineage, however research to confirm such hypotheses in this direction is still lacking.

Keloid Morphology: Cellular and Matrix Composition

On gross examination, keloids are well-demarcated, raised cutaneous lesions in different shapes and may be bosselated, nodular, or pendulous. They may appear shiny with a discoloration—often erythematous with telangiectasia in individuals with fairer skin and hyperpigmented in those with darker skin—and can reach sizes between several millimeters to many centimeters in diameter. Keloids display a heterogenic phenotype in relation to stiffness and range from soft to extremely firm with decreased skin plasticity. The center of keloid tissue often exhibit central hypoxia due to capillary occlusion as a result of exuberant collagen and endothelial cells. Keloid margins contain active fibroblasts which invade into surrounding tissue and are well-vascularized through angiogenesis to upkeep the oxygen and nutrient supply required presumably to fuel their invasiveness. This is thought to be the result of endothelial cell migration and survival from growth factor activation through kinase signaling pathways such as PI3K/AKT, ERK1/2, FAK, and p38/MAPK.

Most of the expansile keloid tissue is in the reticular dermal layer with a thickened overlying epidermis. Keloid tissues are not encapsulated and have a perimeter that advances into the surrounding tissue. Marginal fibroblasts are more metabolically active and engage in higher rates of collagen I and III production, as reflected by more erythematous skin overlying these margins. Several studies have shown that the outer margins and inner complex of keloids are populated by different types of stem cells. In particular, mesenchymal-like stem cells expressing non-hemapoetic markers constituting the inner complex appear to represent the niche that is vital to sustain keloid growth, surrounded by extralesional hematopoietic stem cells. In relation to this, the concentration of homogenous thickened hyalinized collagen in the center surrounded by more typical-looking collagen fibers near the edges is unique to keloids, but not always present.

In brief, cutaneous wound healing involves the formation and remodeling of collagen matrix over time by fibroblasts and myofibroblasts. Similarly, activated myofibroblasts and keloid fibroblasts represent the main generators of keloid matrix through their synergistic action in increasing keloid tissue stiffness. Fibrocytes, thought to be myofibroblast precursors, are bone marrow-derived circulating cells present in keloids and tissues undergoing wound healing. They appear as a cross between fibroblasts, monocytes, and hematopoietic stem cells (HSCs) due to their fibroblast products, hematopoietic surface markers, myeloid antigen expression, and shared morphological characteristics. Their expression of CXCR4 forms part of the CXCR4/SDF-1 axis, which is crucial in skin regulating cutaneous wound healing, systematic lupus erythematosus and angiogenesis of basal cell carcinoma.

The keloid matrix consists of different collagens, glycoproteins, and glycosaminoglycans (GAGs). The initial overproduction of type III collagen in keloid matrix is replaced by type I collagen, with an extremely high ratio of type I to type III collagen (17:1) compared to normal scars (6:1). The collagen fibers constituting keloids are larger than those in normal scars and disorderly arranged in loosely cross-linked whorls of thick bundles in the same plane as the epidermis. Elevated levels of MMP-2, TIMP-1, and TIMP-2 are observed in keloids, the imbalance of which appears to dysregulate collagen production and accumulation, with upregulated MMP-2 and MMP-9 expression additionally linked to cancer invasiveness. Overproduction of collagen and matrix is also linked with dysregulated mTOR signaling, which plays a crucial role in human cancers. Interestingly, elastic fiber deposition is higher in the reticular dermis than the papillary dermis, but has been shown to be absent in the keloid extracellular matrix (ECM) alongside deregulated expression of elastic fiber assembly proteins such as elastin, fibrillin-1 and fibulin-5. This is attributed to the over-deposition of chondroitin sulfate (CS) which is 6.9 times higher than that in normal skin. CS is thought to suppress elastic fiber assembly through the dysregulation of fibrillin-1 deposition and its aberrant expression has been found to contribute to tumor metastasis in breast cancer. The functions of fibulin-5 and elastin in tumor formation are complex, involving the regulation of metalloproteinases (MMPs) amongst others. The interplay between these proteoglycan-associated factors in keloid pathogenesis remain to be elucidated.

Sox9, the master regulator of chondrogenesis, is upregulated in keloids and its ectopic expression is linked with the upregulation of COL2A1 and cartilage oligomeric matrix protein (COMP) which culminates in ECM production geared toward chondrogenesis and fibrosis. COMP stimulates the assembly of collagen 1 fibrils, with an expression level proportional to keloid size and is expressed in scleroderma and other tumors. Keloids exhibit significantly raised levels of biglycan in the nodular dermis of active keloid lesions alongside decreased decorin expression. This is interesting as decorin, which has recently been found to suppress collagen production, is raised in malignant conditions. All these proteoglycans have been shown to be differentially regulated by basic fibroblast growth factor, that is thought to be involved in producing the tumor phenotype.

Keloids share many similarities with other dermal tumors by virtue of their shared tissue origin. This includes the integral activation of Wnt β-catenin pathway in desmoid tumors and elevated levels of TGF-β, collagen, and GAG in dermatofibrosarcoma protuberans. In both of these tumors, trauma has been cited as a precipitating factor.

Keloids and the Hallmarks of Cancer

Although keloids exhibit the hallmarks of cancer to a large extent, these characteristics remain to be fully explored in this context. There is potentially a key regulator or group of pre-requisite factors, which when activated after skin injury, triggers a cascade of events that culminate in keloid scar formation. The various relationships between tumor-related factors expressed in keloids may be complex and their roles in sustaining keloid growth are still unclear. Table 1 highlights key tumor biomarkers discussed in this review.

Sustaining Proliferative Signaling

Keloid fibroblasts express higher receptor tyrosine kinase signals compared to normal skin derived fibroblasts. This increased keloid-derived fibroblast cellular signaling, which may influence cell growth, differentiation, and survival, is linked to cancer development when dysregulated. Nanog, a gene which confers self-replication abilities to cells and is elevated in various cancers, is absent in somatic cells, yet recently found to be upregulated in keloid associated lymphoid tissue (KALT). Zhang et al. described a population of clonogenic, self-renewing keloid-derived precursor cells expressing mesenchymal and embryonic stem cell markers and are driven by IL-6/IL-17 mediated inflammation. IL-6, alongside hepatocyte growth factor and epidermal growth factor, is pro-tumorigenic. Of interest, IL-6 and its second messengers JAK/Stat3, both of which are elevated in keloid fibroblasts, form the IL-6/JAK/Stat3 pathway, which contributes toward tumorigenesis within the tumor micro-environment. In particular, Stat3 confers increased cell proliferation and migration within keloid fibroblasts.

Transforming growth factor beta (TGF-β) is a well-researched cytokine in keloid pathogenesis due to its pivotal role in directing keloid fibrosis. TGF-β1 influences keloid keratinocytes through both Smad-dependent and Smad-independent signaling pathways such as ERK1/2 and p38 to promote collagen accumulation. In relation to cancer, TGF-β1 has been shown to inhibit initial tumor formation before accelerating its malignancy in a transgenic mouse skin cancer model. Keloid and normal fibroblasts exhibit a differential response to PDGF, EGF, FGF, and TGF-β, the majority of which bind to protein tyrosine kinase (PTK) family receptors. PTK receptors contribute to cell proliferation, differentiation, and carcinogenesis.

Satish et al. found the upregulation of ribosomal proteins in keloid fibroblasts, which is also seen in cancer growth, indicating tighter regulations in keloids which prevent the malignant transformation of their precursor cells. Transcriptional activating factors involved include c-jun and c-fos which function as proto-oncogenes. In addition to its role in cell cycle regulation of fibroblasts and Ras-activated human epidermal neoplasia, c-jun is also linked to benign inflammatory conditions like psoriasis and arthritis.

Evasion of Growth Suppressors

The mechanisms underlying keloid growth are not straightforward, involving both up- and downregulation of tumor suppressors. The deregulation of p53 forms the hallmark in various cancers; more recently a mechanism by which it is deregulated in keloids has been identified as TRAF4-USP10 interaction that culminates in fibroblast proliferation. Interestingly, whilst p53 mutation is prevalent in keloids, its expression has also been found to be elevated in the central region of keloid fibroblasts alongside an increase in p63 which inhibits its translation. In turn, this leads to downstream effects including elevated SERPINB5 and maspin, the latter of which is also upregulated during keratinocyte senescence. The link between TP53 codon 72 polymorphism and keloids remains unclear. Other examples include downregulated miR-1224-5p which normally functions through TGF-β1/Smad3, and has a role in cancers. Similarly, miR-21-5p plays a key role in PTEN-mediated proliferative and apoptotic mechanisms in keloid fibroblasts, causing decreased levels of PTEN which is a tumor suppressor with wide-ranging downstream effects on cellular maintenance and morphology through PI3K/AKT/mTOR. Interestingly, elevated levels of tumor suppressors such as PML are also seen in the hypercellular regions of keloids, suggesting senescence as a factor which confers keloids their benign nature. It is plausible that the concerted interplay between these factors result in the quasi-neoplastic behavior of keloids.

Induction of Angiogenesis: The Role of Hypoxia in Keloid Bioenergetics

The Warburg effect is a phenomenon in cancer cells in which metabolism is favored and ATP is produced through anaerobic glycolysis in favor of oxidative metabolism. In cancer cells, the rate of glucose uptake is dramatically increased leading to lactate production, despite the presence of fully functioning mitochondria and availability of oxygen. Specifically, this refers to an increased rate of glycolysis, which is followed by a surge of lactic acid fermentation even if there is no lack of oxygen. Similarly, keloid fibroblasts have been found to preferentially utilize the glycolytic pathway instead of oxidative phosphorylation, the latter of which is utilized by normal fibroblasts. The ability of keloid fibroblasts to tap into a wider source of energy may explain why keloids thrive in a hypoxic microenvironment. Indeed, the same study reported that keloid fibroblasts have more ATP, are 3.7 times more active than normal fibroblasts and exhibit lower levels of reactive oxygen species (ROS), which is a byproduct of mitochondrial oxidative phosphorylation. The switch to aerobic glycolysis in tumors as a means of ATP production is thought to be the result of glycolytic enzymes activated by HIF-α, which is also upregulated in keloids. These findings are supported by the higher levels of lactate in keloids due to glycolysis and increase in keloid ATP synthesis on exposure to hypoxia. As tumors become increasingly reliant on glycolysis with tumor progression, it may even be possible to correlate the growth of keloids with their utilization of glycolysis as a form of keloid disease staging.

Hypoxia is thought to promote tumor proliferation and invasiveness in cancer. In keloids, local hypoxia within the injury zone accelerates wound healing by stimulating angiogenesis and driving fibroblast proliferation, as evidenced by hypoxia-induced vascular endothelial growth factor (VEGF) expression in keloid fibroblasts and a higher density of blood vessels in keloids than normal dermis and scars. In addition to angiogenesis, hypoxia-induced fibroblast to myofibroblast-like conversion has also been observed in keloids and postulated to occur by the TGF-β1/Smad3 pathway. Angiogenesis is vital in the development of many cutaneous diseases. Hypoxia induces the activation of HIF-α1 in both keloids and cancer. This results in the activation of Twist which mediates EMT-related cadherin switching and is a master regulator of morphogenesis and other embryonic processes.

Periostin, a cell-adhesion ECM protein, is increased in physiological processes involved in skin repair, fibrosis, cell proliferation, and ECM remodeling, and tumor processes such as growth and metastasis. Periostin increases angiogenesis by activating ERK1/2 and focal adhesion kinase (FAK) pathways, increasing VEGF and angiopoeitin-1 (Ang-1) expression. Specific to keloids, periostin is associated with promoting the ability of keloid fibroblasts to migrate and invade surrounding tissues in hypoxia. Periostin expression is upregulated by hypoxia through an HIF-1α-dependent pathway. Another group of cell adhesive receptor proteins implicated are integrins which are thought to interact with periostin to facilitate EMT, angiogenesis, and the mobility of chondrocytes, fibroblasts, and cancer cells. Periostin promotes angiogenesis in gastric, breast, and ovarian cancers.

Activating Invasion and Metastasis

There is a growing body of evidence recognizing the importance of EMT in keloid pathophysiology. Whilst EMT is known to promote the migratory behavior of metastatic cells, the benign nature of keloids makes it unclear whether they are the result of type II fibrotic EMT or suspended type III metastatic EMT. There is no evidence of significant epidermal-dermal basement membrane zone (BMZ) breakdown or disrupted collagen IV expression in the BMZ of keloids, which may explain why they do not metastasize. Investigating other cell motility factors in keloids may reveal unique key agents in metastatic prevention.

E-cadherin, a component of epithelial adherens junction, is encoded by CDH1 and becomes lost in cancer cells undergoing EMT. Although CDH1 gene expression levels are similar between normal and keloid keratinocytes, keloids express decreased protein levels of E-cadherin, in line with cadherin switching from E-cadherin to mesenchymal markers such as N-cadherin, fibronectin-1, vimentin, and cadherin-11. Indeed, vimentin, fibronectin-1, and cadherin-11 have been identified in keloids, with overexpression of fibronectin-1. Vimentin, which is commonly expressed in soft tissue tumors, is highly expressed in keloid keratinocytes and associated with changes in shape, motility and adhesion properties during EMT. N-cadherin, which is linked to increased tumor cell mobility and progression, remains to be studied in keloids. Integrin-linked kinase (ILK), which is normally involved in regulating ECM signaling, leads to E-cadherin suppression and promotion of tumor invasiveness alongside a fibroblastic phenotype when aberrantly upregulated in EMT. In basal cell carcinoma, ILK expression leads to increased tumor invasiveness and EMT markers through upregulated Snail, β-catenin and α-SMA. β-catenin is elevated in the nucleus and cytoplasm of cells undergoing EMT. Similarly, a higher level of β-catenin protein activity has been found in keloid keratinocytes compared to normal keratinocytes, and is inversely proportional to E-cadherin expression despite no significant difference at transcription level.

Upon injury, epidermal keratinocytes induce dermal fibroblasts to produce keloid matrix features by expressing genes involved in epithelial-to-mesenchymal transition (EMT) and upregulating the expression of inflammatory mediators such as COX1 and COX2 in keloid fibroblasts, endothelial cells, and inflammatory cells. The fibroblast-like phenotype in these keloid keratinocytes is potentially perpetuated by the local hypoxic environment in keloids which increase the invasiveness of these keratinocytes, thereby leading to excessive keloid growth.

MicroRNAs are known to facilitate oncogenesis and metastasis by regulating post-transcriptional and translational gene expression in cell proliferation, EMT and cancer stem cells. This may explain several observations in keloids, for example, the decreased elastic fiber density in keloids despite normal elastin expression coding for elastic fibers. MiR-21-5p which mediates PTEN in keloids, also contributes to EMT in keloids, thereby suggesting EMT phenotype maintenance in keloid keratinocytes through exertion of their stem-cell like effects. This is significant, as MiR-21-5p has been claimed to be overexpressed in most cancers and various fibrotic disorders such as those involving the skin, kidneys and cardiopulmonary systems.

Additionally, insulin-like growth factor-I receptor, which promotes fibroblast invasiveness, is highly upregulated in keloid fibroblasts compared to normal fibroblasts. Osteopontin is a major cytokine, which promotes matricellular interaction, tumor progression, angiogenesis, and resistance to apoptosis in malignancies. It is expressed in keloids, skin, and mesenchymal tumors. S100 influences the chondroid metaplasia of fibroblasts to fibrocartilage cells and is expressed in desmoplastic melanoma, however it has only been found in low levels in keloids.

Resisting Cell Death

Keloid myofibroblasts are thought to sustain extended “healing” by eluding apoptosis despite prolonged hypoxia. Tumor cells may escape apoptosis through periostin-activated Akt/PKB pathway in hypoxia. In keloids, periostin activation is linked with downstream activation of ERK1/2 which is known to regulate the functions of Fra-1 and ZEB1/2 in tumorigenesis. There is no accepted consensus on the apoptosis levels in keloids. It was previously thought that keloids elude apoptosis by sustaining lower levels of oxidative stress. More recent evidence contradicts this; the discovery of increased ROS and downregulated Nrf2 is consistent with other papers suggesting increased rates of apoptosis in keloids. Nrf2 is protective against oxidative stresses and various diseases including cancer, whereas ROS is thought to act both as a second messenger in intracellular signaling to facilitate cancer progression and as an apoptotic agent by promoting cell senescence. This suggests the possibility of differential response to ROS by different cell populations.

Up to eight apoptosis genes were found to be down-regulated amongst 64 which were studied in keloids, compared to normal skin by Sayah et al.. Amongst these, NIP3 is known pro-apoptotic, induced in response to hypoxia by HIF-1α. The distribution of apoptotic cells was mapped and found to be equal across the normal tissues but were fewer and concentrated at the margins of keloid tissues. From a regional perspective, Luo et al. described in detail the heterogeneous nature of the microenvironment and subcellular regions in keloids with regard to apoptosis. Within the keloid tissue itself, apoptotic cells are concentrated in hypercellular areas at the edges and lacking in the collagen-abundant center, corroborating with previous findings of p53 and Bcl-2 localizing to the same regions. The concerted up- and down- regulation of various apoptotic-related genes in keloid tissues suggest an interplay of these factors in the tumorigenic capabilities of keloids.

Keloids express several heat shock proteins (HSPs) which are responsible for increasing cell survivability through interprotein interactions in response to stresses. HSP47, which is vital in collagen synthesis and maturation, is highly expressed in carcinomas of the head, neck, and pancreas. HSP90 increases in response to cellular stresses to increase cell survival and is upregulated in keloids. Similarly, clusterin is increased in cellular stresses, and invasive tumors.

A study by Yu et al. found increased expression of Wnt10A, β-catenin, and telomerase in keloids. Increased Wnt signaling in keloids promotes cell growth by minimizing apoptosis through upregulation of β-catenin and telomerase activity. In normal cells, β-catenin is inhibited by Sox9 to promote chondrogenesis. It is unclear whether these two molecules are simultaneously upregulated and if so, the effects they have on keloid growth. Telomerase activity, which is linked with disease aggressiveness of bone and soft tissue tumors, is found in 10% of benign and 44% of malignant tumors. Keloid precursor cells have been shown to demonstrate telomerase activity which may mediate telomere lengthening by interacting with IL-6. There are reports, however, of decreased telomere length and suppressed telomerase activity in keloids as it is thought that telomerase ceases to function after the initial stages of keloid formation. Unsurprisingly, telomere length is negatively correlated with ROS levels.

It is postulated that a reciprocal protective relationship exists between tumor cells and their stem cell niche, as shown by the upregulation of various genes and proteins in endothelial cells to increase survivability in response to cytotoxic conditions. The role of micro-environmental signals which promote chemokine-related changes in keloid fibroblasts has been investigated recently following similar studies on epigenetics in cancer development. Studies on DNA methylation profiles of keloid tissue and healthy skin suggest that DNA methylation may be a key driver in the pathology of keloids. These include the discovery of DNMT1 in keloid fibroblasts and master regulator genes such as pyroxamide, tributyrin, PRKG2, and PENK in keloid tissue. Other studies found evidence for histone modification such as upregulated HDAC2 in keloid tissue and expression of non-coding RNAs in keloids. These discoveries are significant as they represent known biomarkers of cancer. HSPs such as HSP27, HSP47, and HSP70 are also found to be overexpressed in keloids, with HSP27 and HSP70 having links to cancer.

Enabling Replicative Immortality: The Role of a Keloid Stem Cell Niche

Stem cells perform various roles in cutaneous wound healing. Distinct populations of several stem or stem-like cells have been identified in keloid tissues, including hematopoietic stem cells, mesenchymal-like stem cells, and keloid progenitor cells. The fate of stem cells dictated by signals from the stem cell niche microenvironment represents a tightly regulated process in keloids.

A population of keloid precursor stem cells (KPCs) was described in the dermis which harbor the capacity for multi-lineage differentiation and self-renewal, the latter of which may explain the high recurrence rates in keloids. Their telomerase activity is higher than normal skin precursor cells but lower than cancers. The significance of this is their correlation with tumor or cancer stem cells which are thought to originate from adult stem cells mutated under the influence of a deregulated stem cell niche, following which they become capable of uncontrolled growth, perpetual self-renewal and multi-lineage differentiation, eventually leading to cancer. They may also have a role in conferring resistance to treatment. The role of the cancer stem cell niche is outlined in further detail by Borovski.

As part of the wound healing process, orchestrated upregulation and interactions between neutrophils, eosinophils, T-cells, B-cells, macrophages, and mast cells have been demonstrated in keloid tissue, and more recently along with keloid-associated lymphoid tissue (KALT). Within KALT, primitive cells within the sub-epidermal micro-vessel endothelium have been recently found to express embryonic stem cell (ESC) markers Oct4, Sox2, pSTAT3, and Nanog, suggesting a possible relationship between the immunogenicity and presence of stem cells in keloids.

Responsiveness to Cancer Treatments

High quality evidence on keloid treatment is limited. Larger keloids often require surgical excision which carry recurrence rates of up to 100% as monotherapy. Radiation, which is another long-established modality of treatment, has been shown to produce varying results in the literature. Primary radiation given to a sample of 84 unresectable keloids over 5 weeks resulted in 97% significant regression in the course of 18 months. Another study found that post-operative radiotherapy in the form of beta radiation at 400cGy twice a week totaling up to 16Gy was found to result in flattened scars in 67% of patients, but not without side effects such as pain and atrophy, and carries a recurrence rate of 21.2%. Brachytherapy has also yielded favorable results, with a recurrence rate of 3.1% at 33.6 months in a recent study. Combined with surgical excision and application of platelet-rich plasma, post-operative superficial radiotherapy up to three fractions has been demonstrated to result in low disease recurrence.

Chemotherapy and targeted therapy agents have also shown promising results. Sorafenib, a tyrosine kinase inhibitor, has been found to be effective in suppressing keloid activity by targeting the TGF-β/Smad and MAPK/ERK pathways which are involved in keloid fibroblast growth and cell cycle processes. A recent systematic review identified post-excision 5-fluorouracil in combination with triamcinolone acetonide as a favorable treatment with up to 92% non-recurrence in what is termed as “combination therapy.” In comparison, monotherapy using intra-lesional corticosteroids, the first-line treatment for keloids has been shown to yield positive results in only 77% of patients. The recurrence rates in triple therapy incorporating surgical excision, intra-lesional steroids, and silicone sheet have been reported at 4.6%, 9.1%, and 12.5%. Keloids are also responsive to recombinant adenovirus-mediated double suicide gene therapy using CDglyTK which is used in cancer.

The use of photodynamic therapy (PDT) in keloids led to the suppression of blood flow and collagen levels alongside improved tissue flexibility. This is a cancer treatment used in Bowen's, basal cell carcinoma and actinic keratosis, thought to suppress fibroproliferation through protoporphyrin 9 (PpIX)-mediated activation of ROS, which is in turn cytotoxic. Although keloids are not metastatic, their responsiveness to multimodal cancer treatment suggests similar underlying disease mechanisms with tumorigenesis.

Conclusion

The idea that keloids behave like non-malignant locally aggressive cutaneous cancers is not new and this is evident in both its phenotypical and genetic properties. The biomarker expression profile in these diseases highlights the striking parallels between keloids and both benign and malignant mesenchymal tumors across transcriptional, translational, cellular, and tissue levels. Keloids also exhibit characteristics displayed by cancer cells to some degree, in particular the Warburg effect which confers increased survival to keloid cells in hypoxia. Furthermore, signaling pathways common to these diseases have been found to mold the matrix composition of keloids with the inclusion of chondrogenic signatures. This, in turn, is perpetuated by key cells such as melanocytes, keratinocytes, fibroblasts, and those from the fibrocytic family, which participate in EMT and possess stem cell-like properties. A keloid stem cell niche has also been postulated to support this. Many important tumor-related factors, which have been shown to contribute to the overall pathogenesis by influencing cellular processes such as apoptosis. To this point in time, the use of cancer treatments in keloids has shown encouraging results, further diminishing the fine line between keloids and cancerous tumors. Taken together, this poses many questions in relation to keloid pathobiology which need to be answered, in order to understand how the cascade encompassing prolonged, dysregulated wound healing culminates in the cancer-like or quasi-neoplastic processes which result in keloid formation, progression, persistence and recurrence. This is vital due to the implications it may have for the future therapy and further investigative research of this elusive disease and those with which it shares similar properties.

Author Contributions

The review article was originally conceived and structured by AB. ST performed literature search and wrote the article. NK contributed by reading and editing. AB edited the overall article.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 272

  1. 1.

    Jumper N Paus R Bayat A. Functional histopathology of keloid disease. Histol Histopathol. (2015 ) 30:1033–57.

    Not in our library10.14670/hh-11-624

  2. 2.

    Lee JY Yang CC Chao SC Wong TW. Histopathological differential diagnosis of keloid and hypertrophic scar. Am J Dermatopathol. (2004 ) 26:379–84.

    Not in our library10.1097/00000372-200410000-00006

  3. 3.

    Ketchum LD Cohen IK Masters FW. Hypertrophic scars and keloids. A collective review. Plastic Reconstr Surg. (1974 ) 53:140–54.

    Not in our library10.1097/00006534-197402000-00004

  4. 4.

    Lu W-s Zheng X-d Yao X-h Zhang L-f. Clinical and epidemiological analysis of keloids in Chinese patients. Arch Dermatol Res. (2015 ) 307:109–14.

    Not in our library10.1007/s00403-014-1507-1

  5. 5.

    English RS Shenefelt PD. Keloids and hypertrophic scars. Dermatol Surg. (1999 ) 25:631–8.

    Not in our library10.1046/j.1524-4725.1999.98257.x

  6. 6.

    Ramakrishnan KM Thomas KP Sundararajan CR. Study of 1,000 patients with keloids in South India. Plastic Reconstr Surg. (1974 ) 53:276–80.

    Not in our library10.1097/00006534-197403000-00004

  7. 7.

    Ud-Din S Bayat A. New insights on keloids, hypertrophic scars, and striae. Dermatol Clin. (2014 ) 32:193–209.

    Not in our library10.1016/j.det.2013.11.002

  8. 8.

    Mustoe TA Cooter RD Gold MH Hobbs FD Ramelet AA Shakespeare PG. International clinical recommendations on scar management. Plastic Reconstr Surg. (2002 ) 110:560–71.

    Not in our library10.1097/00006534-200208000-00031

  9. 9.

    Chipev CC Simon M. Phenotypic differences between dermal fibroblasts from different body sites determine their responses to tension and TGFbeta1. BMC Dermatol. (2002 ) 2:13.

    Not in our library10.1186/1471-5945-2-13

  10. 10.

    Suarez E Syed F Rasgado TA Walmsley A Mandal P Bayat A. Skin equivalent tensional force alters keloid fibroblast behavior and phenotype. Wound Repair Regen. (2014 ) 22:557–68.

    Not in our library10.1111/wrr.12215

  11. 11.

    Kischer CW Shetlar MR Chvapil M. Hypertrophic scars and keloids: a review and new concept concerning their origin. Scan Electron Microsc. (1982 ) (Pt 4):1699–713.

    Not in our library

  12. 12.
    Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis · 2017
    No notice
  13. 13.

    Kazeem AA. The immunological aspects of keloid tumor formation. J Surg Oncol. (1988 ) 38:16–8.

    Not in our library10.1002/jso.2930380106

  14. 14.

    Placik OJ Lewis VL Jr. Immunologic associations of keloids. Surg Gynecol Obstet. (1992 ) 175:185–93.

    Not in our library

  15. 15.

    McCarty SM Syed F Bayat A. Influence of the human leukocyte antigen complex on the development of cutaneous fibrosis: an immunogenetic perspective. Acta Derm Venereol. (2010 ) 90:563–74.

    Not in our library10.2340/00015555-0975

  16. 16.

    Bayat A Arscott G Ollier WE McGrouther DA Ferguson MW. Keloid disease: clinical relevance of single versus multiple site scars. Br J Plastic Surg. (2005 ) 58:28–37.

    Not in our library10.1016/j.bjps.2004.04.024

  17. 17.

    Shih B Bayat A. Genetics of keloid scarring. Arch Dermatol Res. (2010 ) 302:319–39.

    Not in our library10.1007/s00403-009-1014-y

  18. 18.

    Ogawa R Akaishi S. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis—Keloids and hypertrophic scars may be vascular disorders. Med Hypotheses. (2006 ) 96:51–60.

    Not in our library10.1016/j.mehy.2016.09.024

  19. 19.

    Gurtner GC Werner S Barrandon Y Longaker MT. Wound repair and regeneration. Nature. (2008 ) 453:314–21.

    Not in our library10.1038/nature07039

  20. 20.

    Singer AJ Clark RA. Cutaneous wound healing. N Engl J Med. (1999 ) 341:738–46.

    Not in our library10.1056/nejm199909023411006

  21. 21.

    Ferguson MW Whitby DJ Shah M Armstrong J Siebert JW Longaker MT. Scar formation: the spectral nature of fetal and adult wound repair. Plastic Reconstr Surg. (1996 ) 97:854–60.

    Not in our library10.1097/00006534-199604000-00029

  22. 22.

    Vincent AS Phan TT Mukhopadhyay A Lim HY Halliwell B Wong KP. Human skin keloid fibroblasts display bioenergetics of cancer cells. J Invest Dermatol. (2008 ) 128:702–9.

    Not in our library10.1038/sj.jid.5701107

  23. 23.

    Satish L Lyons-Weiler J Hebda PA Wells A. Gene expression patterns in isolated keloid fibroblasts. Wound Repair Regen. (2006 ) 14:463–70.

    Not in our library10.1111/j.1743-6109.2006.00135.x

  24. 24.

    Niessen FB Spauwen PH Schalkwijk J Kon M. On the nature of hypertrophic scars and keloids: a review. Plastic Reconstr Surg. (1999 ) 104:1435–58.

    Not in our library10.1097/00006534-199910000-00031

  25. 25.

    Kimura K Inadomi T Yamauchi W Yoshida Y Kashimura T Terui T. Dermatofibrosarcoma protuberans on the chest with a variety of clinical features masquerading as a keloid: is the disease really protuberant? Ann Dermatol. (2014 ) 26:643–5.

    Not in our library10.5021/ad.2014.26.5.643

  26. 26.

    Kanitakis J. Keloidal dermatofibroma: report of a rare dermatofibroma variant in a young white woman. Am J Dermatopathol. (2013 ) 35:400–1.

    Not in our library10.1097/dad.0b013e31825d9d30

  27. 27.
    Keloidal Atypical Fibroxanthoma: Case and Review of the Literature · 2016
    Not checked
  28. 28.

    Canady J Karrer S Fleck M Bosserhoff AK. Fibrosing connective tissue disorders of the skin: molecular similarities and distinctions. J Dermatol Sci. (2013 ) 70:151–8.

    Not in our library10.1016/j.jdermsci.2013.03.005

  29. 29.

    Bienias W Miȩkoś-Zydek B Kaszuba A Current views on the etiopathogenesis of keloids. Postepy Dermatol Alergol. (2011 ) 28:467–75.

    Not in our library

  30. 30.

    Fletcher CDM Bridge JA Hogendoorn P Mertens F WHO Classification of Tumours. 4th ed IARC (2013 ).

    Not in our library

  31. 31.

    Naitoh M Kubota H Ikeda M Tanaka T Shirane H Suzuki S. Gene expression in human keloids is altered from dermal to chondrocytic and osteogenic lineage. Genes Cells. (2005 ) 10:1081–91.

    Not in our library10.1111/j.1365-2443.2005.00902.x

  32. 32.

    Bayat A Arscott G Ollier WE Ferguson MW Mc Grouther DA. Description of site-specific morphology of keloid phenotypes in an Afrocaribbean population. Br J Plastic Surg. (2004 ) 57:122–33.

    Not in our library10.1016/j.bjps.2003.11.009

  33. 33.

    Crockett DJ. Regional keloid susceptibility. Br J Plastic Surg. (1964 ) 17:245–53.

    Not in our library10.1016/s0007-1226(64)80040-0

  34. 34.

    Kischer CW Thies AC Chvapil M. Perivascular myofibroblasts and microvascular occlusion in hypertrophic scars and keloids. Hum Pathol. (1982 ) 13:819–24.

    Not in our library10.1016/s0046-8177(82)80078-6

  35. 35.

    Bran GM Goessler UR Hormann K Riedel F Sadick H. Keloids: current concepts of pathogenesis (review). Int J Mol Med. (2009 ) 24:283–93.

    Not in our library10.3892/ijmm_00000231

  36. 36.

    Powazniak Y Kempfer AC de la Paz Dominguez M Farias C Keller L Calderazzo JC. Effect of estradiol, progesterone and testosterone on apoptosis- and proliferation-induced MAPK signaling in human umbilical vein endothelial cells. Mol Med Rep. (2009 ) 2:441–7.

    Not in our library10.3892/mmr_00000119

  37. 37.

    Esfahanian N Shakiba Y Nikbin B Soraya H Maleki-Dizaji N Ghazi-Khansari M. Effect of metformin on the proliferation, migration, and MMP-2 and−9 expression of human umbilical vein endothelial cells. Mol Med Rep. (2012 ) 5:1068–74.

    Not in our library10.3892/mmr.2012.753

  38. 38.

    Syed F Ahmadi E Iqbal SA Singh S McGrouther DA Bayat A. Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralesional and extralesional sites: clinical implications for lesional site-directed therapy. Br J Dermatol. (2011 ) 164:83–96.

    Not in our library10.1111/j.1365-2133.2010.10048.x

  39. 39.

    Zhang Q Yamaza T Kelly AP Shi S Wang S Brown J. Tumor-like stem cells derived from human keloid are governed by the inflammatory niche driven by IL-17/IL-6 axis. PLoS ONE. (2009 ) 4:e7798.

    Not in our library10.1371/journal.pone.0007798

  40. 40.

    Iqbal SA Syed F McGrouther DA Paus R Bayat A. Differential distribution of haematopoietic and nonhaematopoietic progenitor cells in intralesional and extralesional keloid: do keloid scars provide a niche for nonhaematopoietic mesenchymal stem cells? Br J Dermatol. (2010 ) 162:1377–83.

    Not in our library10.1111/j.1365-2133.2010.09738.x

  41. 41.

    Huang C Akaishi S Hyakusoku H Ogawa R. Are keloid and hypertrophic scar different forms of the same disorder? A fibroproliferative skin disorder hypothesis based on keloid findings. Int Wound J. (2014 ) 11:517–22.

    Not in our library10.1111/j.1742-481x.2012.01118.x

  42. 42.

    Andrews JP Marttala J Macarak E Rosenbloom J Uitto J. Keloids: The paradigm of skin fibrosis–pathomechanisms and treatment. Matrix Biol. (2016 ) 51:37–46.

    Not in our library10.1016/j.matbio.2016.01.013

  43. 43.

    Ashcroft KJ Syed F Bayat A. Site-specific keloid fibroblasts alter the behaviour of normal skin and normal scar fibroblasts through paracrine signalling. PLoS ONE. (2013 ) 8:e75600.

    Not in our library10.1371/journal.pone.0075600

  44. 44.

    Bellini A Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest. (2007 ) 87:858–70.

    Not in our library10.1038/labinvest.3700654

  45. 45.

    Mori L Bellini A Stacey MA Schmidt M Mattoli S. Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp Cell Res. (2005 ) 304:81–90.

    Not in our library10.1016/j.yexcr.2004.11.011

  46. 46.

    Iqbal SA Sidgwick GP Bayat A. Identification of fibrocytes from mesenchymal stem cells in keloid tissue: a potential source of abnormal fibroblasts in keloid scarring. Arch Dermatol Res. (2012 ) 304:665–71.

    Not in our library10.1007/s00403-012-1225-5

  47. 47.

    Metz CN. Fibrocytes: a unique cell population implicated in wound healing. Cell Mol Life Sci. (2003 ) 60:1342–50.

    Not in our library10.1007/s00018-003-2328-0

  48. 48.

    Bollag WB Hill WD. CXCR4 in epidermal keratinocytes: crosstalk within the skin. J Invest Dermatol. (2013 ) 133:2505–8.

    Not in our library10.1038/jid.2013.271

  49. 49.

    Chen W Fu X Sun X Sun T Zhao Z Sheng Z. Analysis of differentially expressed genes in keloids and normal skin with cDNA microarray. J Surg Res. (2003 ) 113:208–16.

    Not in our library10.1016/s0022-4804(03)00188-4

  50. 50.

    Bux S Madaree A. Keloids show regional distribution of proliferative and degenerate connective tissue elements. Cells Tissues Organs. (2010 ) 191:213–34.

    Not in our library10.1159/000231899

  51. 51.

    Verhaegen PD van Zuijlen PP Pennings NM van Marle J Niessen FB van der Horst CM. Differences in collagen architecture between keloid, hypertrophic scar, normotrophic scar, and normal skin: an objective histopathological analysis. Wound Repair Regen. (2009 ) 17:649–56.

    Not in our library10.1111/j.1524-475x.2009.00533.x

  52. 52.

    Ulrich D Ulrich F Unglaub F Piatkowski A Pallua N. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with different types of scars and keloids. J Plast Reconstr Aesthet Surg. (2010 ) 63:1015–21.

    Not in our library10.1016/j.bjps.2009.04.021

  53. 53.

    Roomi MW Monterrey JC Kalinovsky T Rath M Niedzwiecki A. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep. (2009 ) 21:1323–33.

    Not in our library10.3892/or_00000358

  54. 54.

    Ong CT Khoo YT Mukhopadhyay A Do DV Lim IJ Aalami O. mTOR as a potential therapeutic target for treatment of keloids and excessive scars. Exp Dermatol. (2007 ) 16:394–404.

    Not in our library10.1111/j.1600-0625.2007.00550.x

  55. 55.

    Guertin DA Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. (2007 ) 12:9–22.

    Not in our library10.1016/j.ccr.2007.05.008

  56. 56.

    Chen J Zhuo S Jiang X Zhu X Zheng L Xie S. Multiphoton microscopy study of the morphological and quantity changes of collagen and elastic fiber components in keloid disease. J Biomed Opt. (2011 ) 16:051305.

    Not in our library10.1117/1.3569617

  57. 57.

    Amadeu TP Braune AS Porto LC Desmoulière A Costa AM. Fibrillin-1 and elastin are differentially expressed in hypertrophic scars and keloids. Wound Repair Regen. (2004 ) 12:169–74.

    Not in our library10.1111/j.1067-1927.2004.012209.x

  58. 58.

    Ikeda M Naitoh M Kubota H Ishiko T Yoshikawa K Yamawaki S. Elastic fiber assembly is disrupted by excessive accumulation of chondroitin sulfate in the human dermal fibrotic disease, keloid. Biochem Biophys Res Commun. (2009 ) 390:1221–8.

    Not in our library10.1016/j.bbrc.2009.10.125

  59. 59.
    Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11gene expression in forming surface P-selectin ligands in aggressive breast cancer cells · 2011
    No notice
  60. 60.

    Yanagisawa H Schluterman MK Brekken RA. Fibulin-5, an integrin-binding matricellular protein: its function in development and disease. J Cell Commun Signal. (2009 ) 3:337–47.

    Not in our library10.1007/s12079-009-0065-3

  61. 61.

    Lee YH Albig AR Regner M Schiemann BJ Schiemann WP. Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-beta in mammary epithelial cells via a MMP-dependent mechanism. Carcinogenesis. (2008 ) 29:2243–51.

    Not in our library10.1093/carcin/bgn199

  62. 62.

    Donet M Brassart-Pasco S Salesse S Maquart FX Brassart B. Elastin peptides regulate HT-1080 fibrosarcoma cell migration and invasion through an Hsp90-dependent mechanism. Br J Cancer. (2014 ) 111:139–48.

    Not in our library10.1038/bjc.2014.239

  63. 63.

    Bi W Deng JM Zhang Z Behringer RR de Crombrugghe B. Sox9 is required for cartilage formation. Nat Genet. (1999 ) 22:85–9.

    Not in our library10.1038/8792

  64. 64.

    Hanley KP Oakley F Sugden S Wilson DI Mann DA Hanley NA. Ectopic SOX9 mediates extracellular matrix deposition characteristic of organ fibrosis. J Biol Chem. (2008 ) 283:14063–71.

    Not in our library10.1074/jbc.m707390200

  65. 65.

    Inui S Shono F Nakajima T Hosokawa K Itami S. Identification and characterization of cartilage oligomeric matrix protein as a novel pathogenic factor in keloids. Am J Pathol. (2011 ) 179:1951–60.

    Not in our library10.1016/j.ajpath.2011.06.034

  66. 66.

    Agarwal P Schulz JN Blumbach K Andreasson K Heinegard D Paulsson M. Enhanced deposition of cartilage oligomeric matrix protein is a common feature in fibrotic skin pathologies. Matrix Biol. (2013 ) 32:325–31.

    Not in our library10.1016/j.matbio.2013.02.010

  67. 67.

    Yamamoto M Takahashi H Suzuki C Naishiro Y Yamamoto H Imai K. Cartilage oligomeric matrix protein in systemic sclerosis. Rheumatology. (2007 ) 46:1858–9.

    Not in our library10.1093/rheumatology/kem254

  68. 68.

    Englund E Bartoschek M Reitsma B Jacobsson L Escudero-Esparza A Orimo A. Cartilage oligomeric matrix protein contributes to the development and metastasis of breast cancer. Oncogene. (2016 ) 35:5585–96.

    Not in our library10.1038/onc.2016.98

  69. 69.

    Liu TT Liu XS Zhang M Liu XN Zhu FX Zhu FM. Cartilage oligomeric matrix protein is a prognostic factor and biomarker of colon cancer and promotes cell proliferation by activating the Akt pathway. J Cancer Res Clin Oncol. (2018 ) 144:1049–63.

    Not in our library10.1007/s00432-018-2626-4

  70. 70.

    Hunzelmann N Anders S Sollberg S Schonherr E Krieg T. Co-ordinate induction of collagen type I and biglycan expression in keloids. Br J Dermatol. (1996 ) 135:394–9.

    Not in our library10.1111/j.1365-2133.1996.tb01502.x

  71. 71.

    Adany R Heimer R Caterson B Sorrell JM Iozzo RV. Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. J Biol Chem. (1990 ) 265:11389–96.

    Not in our library

  72. 72.

    Hunzelmann N Schonherr E Bonnekoh B Hartmann C Kresse H Krieg T. Altered immunohistochemical expression of small proteoglycans in the tumor tissue and stroma of basal cell carcinoma. J Invest Dermatol. (1995 ) 104:509–13.

    Not in our library10.1111/1523-1747.ep12605979

  73. 73.

    Tan EM Hoffren J Rouda S Greenbaum S Fox JWt Moore JH Jr. Decorin, versican, and biglycan gene expression by keloid and normal dermal fibroblasts: differential regulation by basic fibroblast growth factor. Exp Cell Res. (1993 ) 209:200–7.

    Not in our library10.1006/excr.1993.1302

  74. 74.

    Turner N Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. (2010 ) 10:116–29.

    Not in our library10.1038/nrc2780

  75. 75.

    Skubitz KM Biology and treatment of aggressive fibromatosis or desmoid tumor. Mayo Clin Proc. (2017 ) 92:947–64.

    Not in our library10.1016/j.mayocp.2017.02.012

  76. 76.

    Locci P Balducci C Lilli C Marinucci L Becchetti E Dolci C. Desmoid and fibroma tumors differently respond to TGFbeta(1) stimulus and ECM macromolecule accumulation. Biomed Pharmacother. (2007 ) 61:131–6.

    Not in our library10.1016/j.biopha.2006.09.011

  77. 77.

    Stivala A Lombardo GA Pompili G Tarico MS Fraggetta F Perrotta RE. Dermatofibrosarcoma protuberans: our experience of 59 cases. Oncol Lett. (2012 ) 4:1047–55.

    Not in our library10.3892/ol.2012.887

  78. 78.

    Hanahan D Weinberg RA. Hallmarks of cancer: the next generation. Cell. (2011 ) 144:646–74.

    Not in our library10.1016/j.cell.2011.02.013

  79. 79.

    Ladin DA Hou Z Patel D McPhail M Olson JC Saed GM. p53 and apoptosis alterations in keloids and keloid fibroblasts. Wound Repair Regen. (1998 ) 6:28–37.

    Not in our library10.1046/j.1524-475x.1998.60106.x

  80. 80.

    Nys K Agostinis P. Bcl-2 family members: essential players in skin cancer. Cancer Lett. (2012 ) 320:1–13.

    Not in our library10.1016/j.canlet.2012.01.031

  81. 81.

    Bovee JV van den Broek LJ Cleton-Jansen AM Hogendoorn PC. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest. (2000 ) 80:1925–34.

    Not in our library10.1038/labinvest.3780202

  82. 82.

    Teofoli P Barduagni S Ribuffo M Campanella A De Pita O Puddu P. Expression of Bcl-2, p53, c-jun and c-fos protooncogenes in keloids and hypertrophic scars. J Dermatol Sci. (1999 ) 22:31–7.

    Not in our library10.1016/s0923-1811(99)00040-7

  83. 83.

    Asano N Yamakazi T Seto M Matsumine A Yoshikawa H Uchida A. The expression and prognostic significance of bone morphogenetic protein-2 in patients with malignant fibrous histiocytoma. J Bone Joint Surg B. (2004 ) 86:607–12.

    Not in our library10.1302/0301-620x.86b4.14484

  84. 84.

    Wilkinson DG Bhatt S Ryseck RP Bravo R. Tissue-specific expression of c-jun and junB during organogenesis in the mouse. Development. (1989 ) 106:465–71.

    Not in our library10.1242/dev.106.3.465

  85. 85.

    Sioletic S Czaplinski J Hu L Fletcher JA Fletcher CD Wagner AJ. c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. J Pathol. (2014 ) 234:190–202.

    Not in our library10.1002/path.4379

  86. 86.

    Laner-Plamberger S Kaser A Paulischta M Hauser-Kronberger C Eichberger T Frischauf AM. Cooperation between GLI and JUN enhances transcription of JUN and selected GLI target genes. Oncogene. (2009 ) 28:1639–51.

    Not in our library10.1038/onc.2009.10

  87. 87.

    Burger JA Kipps TJ. CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood. (2006 ) 107:1761–7.

    Not in our library10.1182/blood-2005-08-3182

  88. 88.

    Shin JU Kim SH Kim H Noh JY Jin S Park CO. TSLP is a potential initiator of collagen synthesis and an activator of CXCR4/SDF-1 axis in keloid pathogenesis. J Invest Dermatol. (2016 ) 136:507–15.

    Not in our library10.1016/j.jid.2015.11.008

  89. 89.

    Zhang Q Oh CK Messadi DV Duong HS Kelly AP Soo C. Hypoxia-induced HIF-1 alpha accumulation is augmented in a co-culture of keloid fibroblasts and human mast cells: involvement of ERK1/2 and PI-3K/Akt. Exp Cell Res. (2006 ) 312:145–55.

    Not in our library10.1016/j.yexcr.2005.10.006

  90. 90.

    Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist. (2004 ) 9(Suppl 5):10–7.

    Not in our library10.1634/theoncologist.9-90005-10

  91. 91.

    Cohly HHP Scott H Ndebele2 K Jenkins JK Angel MF Differential gene expression of fibroblasts: keloid versus normal. Int J Mol Sci. (2002 ) 3:1162–76.

    Not in our library10.3390/i3111162

  92. 92.

    Mehlen P Schulze-Osthoff K Arrigo AP. Small stress proteins as novel regulators of apoptosis. Heat shock protein 27 blocks Fas/APO-1- and staurosporine-induced cell death. J Biol Chem. (1996 ) 271:16510–4.

    Not in our library10.1074/jbc.271.28.16510

  93. 93.

    Garrido C Brunet M Didelot C Zermati Y Schmitt E Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle. (2006 ) 5:2592–601.

    Not in our library10.4161/cc.5.22.3448

  94. 94.

    Kuroda K Tajima S. Proliferation of HSP47-positive skin fibroblasts in dermatofibroma. J Cutan Pathol. (2008 ) 35:21–6.

    Not in our library10.1111/j.1600-0560.2007.00768.x

  95. 95.

    Uozaki H Ishida T Kakiuchi C Horiuchi H Gotoh T Iijima T. Expression of heat shock proteins in osteosarcoma and its relationship to prognosis. Pathol Res Pract. (2000 ) 196:665–73.

    Not in our library10.1016/s0344-0338(00)80118-1

  96. 96.

    Naitoh M Hosokawa N Kubota H Tanaka T Shirane H Sawada M. Upregulation of HSP47 and collagen type III in the dermal fibrotic disease, keloid. Biochem Biophys Res Commun. (2001 ) 280:1316–22.

    Not in our library10.1006/bbrc.2001.4257

  97. 97.

    Whitesell L Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. (2005 ) 5:761–72.

    Not in our library10.1038/nrc1716

  98. 98.

    Lee WJ Lee JH Ahn HM Song SY Kim YO Lew DH. Heat shock protein 90 inhibitor decreases collagen synthesis of keloid fibroblasts and attenuates the extracellular matrix on the keloid spheroid model. Plastic Reconstr Surg. (2015 ) 136:328e−37e.

    Not in our library10.1097/prs.0000000000001538

  99. 99.

    Lim CP Phan TT Lim IJ Cao X. Stat3 contributes to keloid pathogenesis via promoting collagen production, cell proliferation and migration. Oncogene. (2006 ) 25:5416–25.

    Not in our library10.1038/sj.onc.1209531

  100. 100.

    Ghazizadeh M Tosa M Shimizu H Hyakusoku H Kawanami O. Functional implications of the IL-6 signaling pathway in keloid pathogenesis. J Invest Dermatol. (2007 ) 127:98–105.

    Not in our library10.1038/sj.jid.5700564

  101. 101.

    Ong CT Khoo YT Mukhopadhyay A Masilamani J Do DV Lim IJ. Comparative proteomic analysis between normal skin and keloid scar. Br J Dermatol. (2010 ) 162:1302–15.

    Not in our library10.1111/j.1365-2133.2010.09660.x

  102. 102.

    Nickoloff BJ Lingen MW Chang BD Shen M Swift M Curry J. Tumor suppressor maspin is up-regulated during keratinocyte senescence, exerting a paracrine antiangiogenic activity. Cancer Res. (2004 ) 64:2956–61.

    Not in our library10.1158/0008-5472.can-03-2388

  103. 103.

    Zou Z Gao C Nagaich AK Connell T Saito S Moul JW. p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem. (2000 ) 275:6051–4.

    Not in our library10.1074/jbc.275.9.6051

  104. 104.

    Stetler-Stevenson WG Aznavoorian S Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. (1993 ) 9:541–73.

    Not in our library10.1146/annurev.cb.09.110193.002545

  105. 105.

    Curran S Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. (2000 ) 36:1621–30.

    Not in our library10.1016/s0959-8049(00)00156-8

  106. 106.

    Yang HK Jeong KC Kim YK Jung ST. Role of matrix metalloproteinase (MMP) 2 and MMP-9 in soft tissue sarcoma. Clin Orthop Surg. (2014 ) 6:443–54.

    Not in our library10.4055/cios.2014.6.4.443

  107. 107.

    Tanriverdi-Akhisaroglu S Menderes A Oktay G. Matrix metalloproteinase-2 and−9 activities in human keloids, hypertrophic and atrophic scars: a pilot study. Cell Biochem Funct. (2009 ) 27:81–7.

    Not in our library10.1002/cbf.1537

  108. 108.

    Li H Nahas Z Feng F Elisseeff JH Boahene K. Tissue engineering for in vitro analysis of matrix metalloproteinases in the pathogenesis of keloid lesions. JAMA Facial Plast Surg. (2013 ) 15:448–56.

    Not in our library10.1001/jamafacial.2013.1211

  109. 109.

    Pardo PS Leung JK Lucchesi JC Pereira-Smith OM. MRG15, a novel chromodomain protein, is present in two distinct multiprotein complexes involved in transcriptional activation. J Biol Chem. (2002 ) 277:50860–6.

    Not in our library10.1074/jbc.m203839200

  110. 110.

    Syed F Sherris D Paus R Varmeh S Singh S Pandolfi PP. Keloid disease can be inhibited by antagonizing excessive mTOR signaling with a novel dual TORC1/2 inhibitor. Am J Pathol. (2012 ) 181:1642–58.

    Not in our library10.1016/j.ajpath.2012.08.006

  111. 111.

    Jeter CR Yang T Wang J Chao HP Tang DG. Concise review: NANOG in cancer stem cells and tumor development: an update and outstanding questions. Stem Cells. (2015 ) 33:2381–90.

    Not in our library10.1002/stem.2007

  112. 112.

    Grant C Chudakova DA Itinteang T Chibnall AM Brasch HD Davis PF. Expression of embryonic stem cell markers in keloid-associated lymphoid tissue. J Clin Pathol. (2016 ) 69:643–6.

    Not in our library10.1136/jclinpath-2015-203483

  113. 113.

    Wicki A Lehembre F Wick N Hantusch B Kerjaschki D Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: Podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. (2006 ) 9:261–72.

    Not in our library10.1016/j.ccr.2006.03.010

  114. 114.

    Sayah DN Soo C Shaw WW Watson J Messadi D Longaker MT. Downregulation of apoptosis-related genes in keloid tissues. J Surg Res. (1999 ) 87:209–16.

    Not in our library10.1006/jsre.1999.5761

  115. 115.
    Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia · 2000
    Not checked
  116. 116.

    Sowter HM Ratcliffe PJ Watson P Greenberg AH Harris AL. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. (2001 ) 61:6669–73. Available online at: http://cancerres.aacrjournals.org/content/61/18/6669

    Not in our library

  117. 117.

    Dotto GP. Notch tumor suppressor function. Oncogene. (2008 ) 27:5115–23.

    Not in our library10.1038/onc.2008.225

  118. 118.

    Syed F Bayat A. Notch signaling pathway in keloid disease: enhanced fibroblast activity in a Jagged-1 peptide-dependent manner in lesional vs. extralesional fibroblasts. Wound Repair Regen. (2012 ) 20:688–706.

    Not in our library10.1111/j.1524-475x.2012.00823.x

  119. 119.

    Liu L Zhang J Fang C Zhang Z Feng Y Xi X. OCT4 mediates FSH-induced epithelial-mesenchymal transition and invasion through the ERK1/2 signaling pathway in epithelial ovarian cancer. Biochem Biophys Res Commun. (2015 ) 461:525–32.

    Not in our library10.1016/j.bbrc.2015.04.061

  120. 120.

    Shevde LA Samant RS. Role of osteopontin in the pathophysiology of cancer. Matrix Biol. (2014 ) 37:131–41.

    Not in our library10.1016/j.matbio.2014.03.001

  121. 121.

    Miragliotta V Pirone A Donadio E Abramo F Ricciardi MP Theoret CL. Osteopontin expression in healing wounds of horses and in human keloids. Equine Vet J. (2016 ) 48:72–7.

    Not in our library10.1111/evj.12372

  122. 122.

    Lu F Gao J Ogawa R Hyakusoku H Ou C. Biological differences between fibroblasts derived from peripheral and central areas of keloid tissues. Plastic Reconstr Surg. (2007 ) 120:625–30.

    Not in our library10.1097/01.prs.0000270293.93612.7b

  123. 123.

    Hollstein M Sidransky D Vogelstein B Harris CC. p53 mutations in human cancers. Science. (1991 ) 253:49–53.

    Not in our library10.1126/science.1905840

  124. 124.

    Yang A McKeon F. P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol. (2000 ) 1:199–207.

    Not in our library10.1038/35043127

  125. 125.

    De Felice B Garbi C Santoriello M Santillo A Wilson RR. Differential apoptosis markers in human keloids and hypertrophic scars fibroblasts. Mol Cell Biochem. (2009 ) 327:191–201.

    Not in our library10.1007/s11010-009-0057-x

  126. 126.

    Maues De Paula A Vasiljevic A Giorgi R Gomez-Brouchet A Aubert S Leroy X. A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50% of cells is stained. Virchows Arch. (2014 ) 465:487–94.

    Not in our library10.1007/s00428-014-1637-z

  127. 127.

    Demoulin JB Essaghir A. PDGF receptor signaling networks in normal and cancer cells. Cytokine Growth Factor Rev. (2014 ) 25:273–83.

    Not in our library10.1016/j.cytogfr.2014.03.003

  128. 128.

    Norris RA Damon B Mironov V Kasyanov V Ramamurthi A Moreno-Rodriguez R. Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J Cell Biochem. (2007 ) 101:695–711.

    Not in our library10.1002/jcb.21224

  129. 129.

    Fukuda K Sugihara E Ohta S Izuhara K Funakoshi T Amagai M. Periostin is a key niche component for wound metastasis of melanoma. PLoS ONE. (2015 ) 10:e0129704.

    Not in our library10.1371/journal.pone.0129704

  130. 130.

    Baeuerle PA Rupec RA Pahl HL. Reactive oxygen intermediates as second messengers of a general pathogen response. Pathol Biol. (1996 ) 44:29–35.

    Not in our library

  131. 131.

    De Felice B Wilson RR Nacca M. Telomere shortening may be associated with human keloids. BMC Med Genet. (2009 ) 10:110.

    Not in our library10.1186/1471-2350-10-110

  132. 132.

    Hunasgi S Koneru A Vanishree M Shamala R. Keloid: acase report and review of pathophysiology and differences between keloid and hypertrophic scars. J Oral Maxillofac Pathol. (2013 ) 17:116–20.

    Not in our library10.4103/0973-029x.110701

  133. 133.

    Gebhardt C Riehl A Durchdewald M Nemeth J Furstenberger G Muller-Decker K. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med. (2008 ) 205:275–85.

    Not in our library10.1084/jem.20070679

  134. 134.

    Basu-Roy U Seo E Ramanathapuram L Rapp TB Perry JA Orkin SH. Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene. (2012 ) 31:2270–82.

    Not in our library10.1038/onc.2011.405

  135. 135.

    Boumahdi S Driessens G Lapouge G Rorive S Nassar D Le Mercier M. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature. (2014 ) 511:246–50.

    Not in our library10.1038/nature13305

  136. 136.

    Wehrli BM Huang W De Crombrugghe B Ayala AG Czerniak B. Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors. Hum Pathol. (2003 ) 34:263–9.

    Not in our library10.1053/hupa.2003.41

  137. 137.

    Bowman T Garcia R Turkson J Jove R. STATs in oncogenesis. Oncogene. (2000 ) 19:2474–88.

    Not in our library10.1038/sj.onc.1203527

  138. 138.

    Bromberg JF Wrzeszczynska MH Devgan G Zhao Y Pestell RG Albanese C. Stat3 as an oncogene. Cell. (1999 ) 98:295–303.

    Not in our library10.1016/s0092-8674(00)81959-5

  139. 139.

    Xue H McCauley RL Zhang W. Elevated interleukin-6 expression in keloid fibroblasts. J Surg Res. (2000 ) 89:74–7.

    Not in our library10.1006/jsre.1999.5805

  140. 140.
    Wnt/β-Catenin Signaling Exacerbates Keloid Cell Proliferation by Regulating Telomerase · 2016
    Not checked
  141. 141.

    Igota S Tosa M Murakami M Egawa S Shimizu H Hyakusoku H. Identification and characterization of Wnt signaling pathway in keloid pathogenesis. Int J Med Sci. (2013 ) 10:344–54.

    Not in our library10.7150/ijms.5349

  142. 142.

    Kirikoshi H Inoue S Sekihara H Katoh M. Expression of WNT10A in human cancer. Int J Oncol. (2001 ) 19:997–1001.

    Not in our library10.3892/ijo.19.5.997

  143. 143.

    Chin GS Liu W Peled Z Lee TY Steinbrech DS Hsu M. Differential expression of transforming growth factor-beta receptors I and II and activation of Smad 3 in keloid fibroblasts. Plast Reconstr Surg. (2001 ) 108:423–9.

    Not in our library10.1097/00006534-200108000-00022

  144. 144.

    Chin GS Liu W Steinbrech D Hsu M Levinson H Longaker MT. Cellular signaling by tyrosine phosphorylation in keloid and normal human dermal fibroblasts. Plastic Reconstr Surg. (2000 ) 106:1532–40.

    Not in our library10.1097/00006534-200012000-00014

  145. 145.

    Lodish H Berk A Zipursky SL Matsudaira P Baltimore D Darnell J Receptor Tyrosine Kinases and Ras. Molecular Cell Biology. 4th ed New York, NY: W. H. Freeman (2000 ).

    Not in our library

  146. 146.

    Chambers I Colby D Robertson M Nichols J Lee S Tweedie S. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. (2003 ) 113:643–55.

    Not in our library10.1016/s0092-8674(03)00392-1

  147. 147.

    Mitsui K Tokuzawa Y Itoh H Segawa K Murakami M Takahashi K. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. (2003 ) 113:631–42.

    Not in our library10.1016/s0092-8674(03)00393-3

  148. 148.

    Chambers I. The molecular basis of pluripotency in mouse embryonic stem cells. Cloning Stem Cells. (2004 ) 6:386–91.

    Not in our library10.1089/clo.2004.6.386

  149. 149.

    Chang Q Bournazou E Sansone P Berishaj M Gao SP Daly L. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia. (2013 ) 15:848–62.

    Not in our library10.1593/neo.13706

  150. 150.

    Bettinger DA Yager DR Diegelmann RF Cohen IK. The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis. Plastic Reconstr Surg. (1996 ) 98:827–33.

    Not in our library10.1097/00006534-199610000-00012

  151. 151.

    Jagadeesan J Bayat A. Transforming growth factor beta (TGFbeta) and keloid disease. Int J Surg. (2007 ) 5:278–85.

    Not in our library10.1016/j.ijsu.2006.04.007

  152. 152.

    Cui W Fowlis DJ Bryson S Duffie E Ireland H Balmain A. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell. (1996 ) 86:531–42.

    Not in our library10.1016/s0092-8674(00)80127-0

  153. 153.

    Haisa M Okochi H Grotendorst GR. Elevated levels of PDGF alpha receptors in keloid fibroblasts contribute to an enhanced response to PDGF. J Invest Dermatol. (1994 ) 103:560–3.

    Not in our library10.1111/1523-1747.ep12396856

  154. 154.

    Babu M Diegelmann R Oliver N. Keloid fibroblasts exhibit an altered response to TGF-beta. J Invest Dermatol. (1992 ) 99:650–5.

    Not in our library10.1111/1523-1747.ep12668146

  155. 155.

    Ullrich A Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. (1990 ) 61:203–12.

    Not in our library10.1016/0092-8674(90)90801-k

  156. 156.

    Kolibaba KS Druker BJ. Protein tyrosine kinases and cancer. Biochim Biophys Acta. (1997 ) 1333:F217–48.

    Not in our library10.1016/s0304-419x(97)00022-x

  157. 157.

    Zenz R Efer R Kenner L Florin L Hummerich L Mehic D. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature. (2005 ) 437:369–75.

    Not in our library10.1038/nature03963

  158. 158.

    Deng CC Zhu DH Chen YJ Huang TY Peng Y Liu SY. TRAF4 promotes fibroblast proliferation in keloids by destabilizing p53 via interacting with the deubiquitinase USP10. J Invest Dermatol. (2019 ).

    Not in our library10.1016/j.jid.2019.03.1136

  159. 159.

    Saed GM Ladin D Olson J Han X Hou Z Fivenson D. Analysis of p53 gene mutations in keloids using polymerase chain reaction-based single-strand conformational polymorphism and DNA sequencing. Arch Dermatol. (1998 ) 134:963–7.

    Not in our library10.1001/archderm.134.8.963

  160. 160.

    Kaneishi NK Cockerell CJ. Histologic differentiation of desmoplastic melanoma from cicatrices. Am J Dermatopathol. (1998 ) 20:128–34.

    Not in our library10.1097/00000372-199804000-00004

  161. 161.

    Yan L Lü XY Wang CM Cao R Yin YH Jia CS. Association between p53 gene codon 72 polymorphism and keloid in Chinese population. Zhonghua Zheng Xing Wai Ke Za Zhi. (2007 ) 23:428−30.

    Not in our library

  162. 162.

    Zhuo Y Gao JH Luo SQ Zeng WS Hu ZQ Lu F. p53 gene codon 72 polymorphism and susceptibility to keloid in Chinese population. Zhonghua Zheng Xing Wai Ke Za Zhi. (2005 ) 19:28–30.

    Not in our library

  163. 163.

    Yao X Cui X Wu X Xu P Zhu W Chen X. Tumor suppressive role of miR-1224-5p in keloid proliferation, apoptosis and invasion via the TGF-β1/Smad3 signaling pathway. Biochem Biophys Res Commun. (2018 ) 495:713–20.

    Not in our library10.1016/j.bbrc.2017.10.070

  164. 164.

    Liu Y Wang X Yang D Xiao Z Chen X. MicroRNA-21 affects proliferation and apoptosis by regulating expression of PTEN in human keloid fibroblasts. Plastic Reconstr Surg. (2014 ) 134:561e−73e.

    Not in our library10.1097/prs.0000000000000577

  165. 165.
    PTEN: Tumor Suppressor and Metabolic Regulator · 2018
    No notice
  166. 166.

    Varmeh S Egia A McGrouther D Tahan SR Bayat A Pandolfi PP. Cellular senescence as a possible mechanism for halting progression of keloid lesions. Genes Cancer. (2011 ) 2:1061–6.

    Not in our library10.1177/1947601912440877

  167. 167.

    Vander Heiden MG Cantley LC Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. (2009 ) 324:1029–33.

    Not in our library10.1126/science.1160809

  168. 168.

    Warburg O. On the origin of cancer cells. Science. (1956 ) 123:309–14.

    Not in our library10.1126/science.123.3191.309

  169. 169.

    Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Ann Rev Cell Dev Biol. (1999 ) 15:551–78.

    Not in our library10.1146/annurev.cellbio.15.1.551

  170. 170.

    Zhang Q Wu Y Ann DK Messadi DV Tuan TL Kelly AP. Mechanisms of hypoxic regulation of plasminogen activator inhibitor-1 gene expression in keloid fibroblasts. J Invest Dermatol. (2003 ) 121:1005–12.

    Not in our library10.1046/j.1523-1747.2003.12564.x

  171. 171.

    Wu Y Zhang Q Ann DK Akhondzadeh A Duong HS Messadi DV. Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts. Am J Physiol Cell Physiol. (2004 ) 286:C905–12.

    Not in our library10.1152/ajpcell.00200.2003

  172. 172.

    Hoopes JE Su CT Im MJ. Enzyme activities in hypertrophic scars and keloids. Plast Reconstr Surg. (1971 ) 47:132–7.

    Not in our library10.1097/00006534-197102000-00006

  173. 173.

    Ramanathan A Wang C Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA. (2005 ) 102:5992–7.

    Not in our library10.1073/pnas.0502267102

  174. 174.

    Mucaj V Shay JE Simon MC. Effects of hypoxia and HIFs on cancer metabolism. Int J Hematol. (2012 ) 95:464–70.

    Not in our library10.1007/s12185-012-1070-5

  175. 175.

    Lokmic Z Musyoka J Hewitson TD Darby IA. Hypoxia and hypoxia signaling in tissue repair and fibrosis. Int Rev Cell Mol Biol. (2012 ) 296:139–85.

    Not in our library10.1016/b978-0-12-394307-1.00003-5

  176. 176.

    Steinbrech DS Mehrara BJ Chau D Rowe NM Chin G Lee T. Hypoxia upregulates VEGF production in keloid fibroblasts. Ann Plast Surg. (1999 ) 42:514–9.

    Not in our library10.1097/00000637-199905000-00009

  177. 177.

    Zhao B Guan H Liu JQ Zheng Z Zhou Q Zhang J. Hypoxia drives the transition of human dermal fibroblasts to a myofibroblast-like phenotype via the TGF-beta1/Smad3 pathway. Int J Mol Med. (2017 ) 39:153–9.

    Not in our library10.3892/ijmm.2016.2816

  178. 178.

    Laquer V Hoang V Nguyen A Kelly KM. Angiogenesis in cutaneous disease: part II. J Am Acad Dermatol. (2000 ) 61:945–58.

    Not in our library10.1016/j.jaad.2009.05.053

  179. 179.

    O'Connell MP Weeraratna AT. Change is in the air: the hypoxic induction of phenotype switching in melanoma. J Invest Dermatol. (2013 ) 133:2316–7.

    Not in our library10.1038/jid.2013.208

  180. 180.

    Yang MH Wu KJ. TWIST activation by hypoxia inducible factor-1 (HIF-1): Implications in metastasis and development. Cell Cycle. (2008 ) 7:2090–6.

    Not in our library10.4161/cc.7.14.6324

  181. 181.

    Zhou HM Wang J Elliott C Wen W Hamilton DW Conway SJ. Spatiotemporal expression of periostin during skin development and incisional wound healing: lessons for human fibrotic scar formation. J Cell Commun Signal. (2010 ) 4:99–107.

    Not in our library10.1007/s12079-010-0090-2

  182. 182.

    Zhang Z Nie F Chen X Qin Z Kang C Chen B. Upregulated periostin promotes angiogenesis in keloids through activation of the ERK 1/2 and focal adhesion kinase pathways, as well as the upregulated expression of VEGF and angiopoietin1. Mol Med Rep. (2015 ) 11:857–64.

    Not in our library10.3892/mmr.2014.2827

  183. 183.

    Zhang Z Nie F Kang C Chen B Qin Z Ma J. Increased periostin expression affects the proliferation, collagen synthesis, migration and invasion of keloid fibroblasts under hypoxic conditions. Int J Mol Med. (2014 ) 34:253–61.

    Not in our library10.3892/ijmm.2014.1760

  184. 184.

    Ruan K Bao S Ouyang G. The multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci. (2009 ) 66:2219–30.

    Not in our library10.1007/s00018-009-0013-7

  185. 185.

    Zhu M Fejzo MS Anderson L Dering J Ginther C Ramos L. Periostin promotes ovarian cancer angiogenesis and metastasis. Gynecol Oncol. (2010 ) 119:337–44.

    Not in our library10.1016/j.ygyno.2010.07.008

  186. 186.

    Qiu F Shi CH Zheng J Liu YB. Periostin mediates the increased pro-angiogenic activity of gastric cancer cells under hypoxic conditions. J Biochem Mol Toxicol. (2013 ) 27:364–9.

    Not in our library10.1002/jbt.21498

  187. 187.

    Kalluri R Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. (2009 ) 119:1420–8.

    Not in our library10.1172/jci39104

  188. 188.

    Hahn JM McFarland KL Combs KA Supp DM. Partial epithelial-mesenchymal transition in keloid scars: regulation of keloid keratinocyte gene expression by transforming growth factor-β1. Burns Trauma. (2016 ) 4:30.

    Not in our library10.1186/s41038-016-0055-7

  189. 189.

    Zeisberg M Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. (2009 ) 119:1429–37.

    Not in our library10.1172/jci36183

  190. 190.

    Yan L Cao R Wang L Liu Y Pan B Yin Y Epithelial-mesenchymal transition (EMT) in keloid tissues and TGF-beta1-induced hair follicle outer root sheath keratinocytes. Wound Repair Regen. (2015 ) 23:601–10.

    Not in our library10.1111/wrr.12320

  191. 191.

    Wheelock MJ Shintani Y Maeda M Fukumoto Y Johnson KR. Cadherin switching. J Cell Sci. (2008 ) 121:727–35.

    Not in our library10.1242/jcs.000455

  192. 192.

    Mendez MG Kojima SI Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. (2010 ) 24:1838–51.

    Not in our library10.1096/fj.09-151639

  193. 193.

    Hulit J Suyama K Chung S Keren R Agiostratidou G Shan W. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res. (2007 ) 67:3106–16.

    Not in our library10.1158/0008-5472.can-06-3401

  194. 194.

    Hazan RB Qiao R Keren R Badano I Suyama K. Cadherin switch in tumor progression. Ann N Y Acad Sci. (2004 ) 1014:155–63.

    Not in our library10.1196/annals.1294.016

  195. 195.

    Hannigan GE Leung-Hagesteijn C Fitz-Gibbon L Coppolino MG Radeva G Filmus J. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature. (1996 ) 379:91–6.

    Not in our library10.1038/379091a0

  196. 196.

    Dedhar S. Cell-substrate interactions and signaling through ILK. Curr Opin Cell Biol. (2000 ) 12:250–6.

    Not in our library10.1016/s0955-0674(99)00083-6

  197. 197.

    Papanikolaou S Bravou V Gyftopoulos K Nakas D Repanti M Papadaki H. ILK expression in human basal cell carcinoma correlates with epithelial-mesenchymal transition markers and tumour invasion. Histopathology. (2010 ) 56:799–809.

    Not in our library10.1111/j.1365-2559.2010.03556.x

  198. 198.

    Cano A Pérez-Moreno MA Rodrigo I Locascio A Blanco MJ Del Barrio MG. The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. (2000 ) 2:76–83.

    Not in our library10.1038/35000025

  199. 199.

    Poser I Dominguez D de Herreros AG Varnai A Buettner R Bosserhoff AK. Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. J Biol Chem. (2001 ) 276:24661–6.

    Not in our library10.1074/jbc.m011224200

  200. 200.

    Cheng CW Wu PE Yu JC Huang CS Yue CT Wu CW. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene. (2001 ) 20:3814–23.

    Not in our library10.1038/sj.onc.1204505

  201. 201.

    Hahn JM Glaser K McFarland KL Aronow BJ Boyce ST Supp DM. Keloid-derived keratinocytes exhibit an abnormal gene expression profile consistent with a distinct causal role in keloid pathology. Wound Repair Regen. (2013 ) 21:530–44.

    Not in our library10.1111/wrr.12060

  202. 202.

    Abdou AG Maraee AH Abd-Elsattar Saif HF. Immunohistochemical evaluation of cox-1 and cox-2 expression in keloid and hypertrophic scar. Am J Dermatopathol. (2014 ) 36:311–7.

    Not in our library10.1097/dad.0b013e3182a27b83

  203. 203.

    Sanchez-Diaz PC Hsiao TH Chang JC Yue D Tan MC Chen HI. De-regulated microRNAs in pediatric cancer stem cells target pathways involved in cell proliferation, cell cycle and development. PLoS ONE. (2013 ) 8:e61622.

    Not in our library10.1371/journal.pone.0061622

  204. 204.

    Hao J Zhang Y Deng M Ye R Zhao S Wang Y. MicroRNA control of epithelial-mesenchymal transition in cancer stem cells. Int J Cancer. (2014 ) 135:1019–27.

    Not in our library10.1002/ijc.28761

  205. 205.

    Liu Y Yang D Xiao Z Zhang M. MiRNA expression profiles in keloid tissue and corresponding normal skin tissue. Aesthetic Plast Surg. (2012 ) 36:193–201.

    Not in our library10.1007/s00266-011-9773-1

  206. 206.

    Yan L Cao R Liu Y Wang L Pan B Lv X. MiR-21-5p links epithelial-mesenchymal transition phenotype with stem-like cell signatures via AKT signaling in keloid keratinocytes. Sci Rep. (2016 ) 6:28281.

    Not in our library10.1038/srep28281

  207. 207.

    Kumarswamy R Volkmann I Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol. (2011 ) 8:706–13.

    Not in our library10.4161/rna.8.5.16154

  208. 208.

    Yoshimoto H Ishihara H Ohtsuru A Akino K Murakami R Kuroda H. Overexpression of insulin-like growth factor-1 (IGF-I) receptor and the invasiveness of cultured keloid fibroblasts. Am J Pathol. (1999 ) 154:883–9.

    Not in our library10.1016/s0002-9440(10)65335-7

  209. 209.

    Narama I Masuoka-Nishiyama M Matsuura T Ozaki K Nagatani M Morishima T. Morphogenesis of degenerative changes predisposing dogs to rupture of the cranial cruciate ligament. J Vet Med Sci. (1996 ) 58:1091–7.

    Not in our library10.1292/jvms.58.11_1091

  210. 210.

    Desmouliere A Chaponnier C Gabbiani G. Tissue repair, contraction, and the myofibroblast. Wound Repair Regen. (2005 ) 13:7–12.

    Not in our library10.1111/j.1067-1927.2005.130102.x

  211. 211.

    Bao S Ouyang G Bai X Huang Z Ma C Liu M. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell. (2004 ) 5:329–39.

    Not in our library10.1016/s1535-6108(04)00081-9

  212. 212.

    Shin S Dimitri CA Yoon SO Dowdle W Blenis J ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell. (2010 ) 38:114–27.

    Not in our library10.1016/j.molcel.2010.02.020

  213. 213.

    Calderon M Lawrence WT Banes AJ. Increased proliferation in keloid fibroblasts wounded in vitro. J Surg Res. (1996 ) 61:343–7.

    Not in our library10.1006/jsre.1996.0127

  214. 214.

    Lee YJ Kwon SB Kim CH Cho HD Nam HS Lee SH. Oxidative damage and nuclear factor erythroid 2-related factor 2 protein expression in normal skin and keloid tissue. Ann Dermatol. (2015 ) 27:507–16.

    Not in our library10.5021/ad.2015.27.5.507

  215. 215.

    Akasaka Y Ishikawa Y Ono I Fujita K Masuda T Asuwa N. Enhanced expression of caspase-3 in hypertrophic scars and keloid: induction of caspase-3 and apoptosis in keloid fibroblasts in vitro. Lab Invest. (2000 ) 80:345–57.

    Not in our library10.1038/labinvest.3780039

  216. 216.

    Appleton I Brown NJ Willoughby DA. Apoptosis, necrosis, and proliferation: possible implications in the etiology of keloids. Am J Pathol. (1996 ) 149:1441–7.

    Not in our library

  217. 217.

    Motohashi H Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med. (2004 ) 10:549–57.

    Not in our library10.1016/j.molmed.2004.09.003

  218. 218.

    Lau A Villeneuve NF Sun Z Wong PK Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res. (2008 ) 58:262–70.

    Not in our library10.1016/j.phrs.2008.09.003

  219. 219.

    Chen QM Bartholomew JC Campisi J Acosta M Reagan JD Ames BN Molecular analysis of H2O2-induced senescent-like growth arrest in normal human fibroblasts: p53 and Rb control G1 arrest but not cell replication. Biochem J. (1998 ) 332(Pt 1):43–50.

    Not in our library10.1042/bj3320043

  220. 220.

    Luo S Benathan M Raffoul W Panizzon RG Egloff DV. Abnormal balance between proliferation and apoptotic cell death in fibroblasts derived from keloid lesions. Plastic Reconstr Surg. (2001 ) 107:87–96.

    Not in our library10.1097/00006534-200101000-00014

  221. 221.

    Akasaka Y Fujita K Ishikawa Y Asuwa N Inuzuka K Ishihara M. Detection of apoptosis in keloids and a comparative study on apoptosis between keloids, hypertrophic scars, normal healed flat scars, and dermatofibroma. Wound Repair Regen. (2001 ) 9:501–6.

    Not in our library10.1046/j.1524-475x.2001.00501.x

  222. 222.

    Beere HM “The stress of dying”: the role of heat shock proteins in the regulation of apoptosis. J Cell Sci. (2004 ) 117(Pt 13):2641–51.

    Not in our library10.1242/jcs.01284

  223. 223.

    Sauk JJ Nikitakis N Siavash H. Hsp47 a novel collagen binding serpin chaperone, autoantigen and therapeutic target. Front Biosci. (2005 ) 10:107–18.

    Not in our library10.2741/1513

  224. 224.

    Welkoborsky HJ Bernauer HS Riazimand HS Jacob R Mann WJ Hinni ML. Patterns of chromosomal aberrations in metastasizing and nonmetastasizing squamous cell carcinomas of the oropharynx and hypopharynx. Ann Otol Rhinol Laryngol. (2000 ) 109:401–10.

    Not in our library10.1177/000348940010900411

  225. 225.

    Maitra A Iacobuzio-Donahue C Rahman A Sohn TA Argani P Meyer R. Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47. Am J Clin Pathol. (2002 ) 118:52–9.

    Not in our library10.1309/3pam-p5wl-2lv0-r4eg

  226. 226.

    Djeu JY Wei S. Clusterin and chemoresistance. Adv Cancer Res. (2009 ) 105:77–92.

    Not in our library10.1016/s0065-230x(09)05005-2

  227. 227.

    Shannan B Seifert M Leskov K Willis J Boothman D Tilgen W. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ. (2006 ) 13:12–9.

    Not in our library10.1038/sj.cdd.4401779

  228. 228.

    Trougakos IP Djeu JY Gonos ES Boothman DA. Advances and challenges in basic and translational research on clusterin. Cancer Res. (2009 ) 69:403–6.

    Not in our library10.1158/0008-5472.can-08-2912

  229. 229.

    Akiyama H Lyons JP Mori-Akiyama Y Yang X Zhang R Zhang Z. Interactions between Sox9 and beta-catenin control chondrocyte differentiation. Genes Dev. (2004 ) 18:1072–87.

    Not in our library10.1101/gad.1171104

  230. 230.

    Yano F Kugimiya F Ohba S Ikeda T Chikuda H Ogasawara T. The canonical Wnt signaling pathway promotes chondrocyte differentiation in a Sox9-dependent manner. Biochem Biophys Res Commun. (2005 ) 333:1300–8.

    Not in our library10.1016/j.bbrc.2005.06.041

  231. 231.

    Umehara N Ozaki T Sugihara S Kunisada T Morimoto Y Kawai A. Influence of telomerase activity on bone and soft tissue tumors. J Cancer Res Clin Oncol. (2004 ) 130:411–6.

    Not in our library10.1007/s00432-004-0553-z

  232. 232.

    Granick M Kimura M Kim S Daniali L Cao X Herbig U. Telomere dynamics in keloids. Eplasty. (2011 ) 11:e15.

    Not in our library

  233. 233.
    Oxidative Stress Induces Persistent Telomeric DNA Damage Responsible for Nuclear Morphology Change in Mammalian Cells · 2014
    No notice
  234. 234.

    Ezhilarasan R Mohanam I Govindarajan K Mohanam S. Glioma cells suppress hypoxia-induced endothelial cell apoptosis and promote the angiogenic process. Int J Oncol. (2007 ) 30:701–7.

    Not in our library10.3892/ijo.30.3.701

  235. 235.

    Brown CK Khodarev NN Yu J Moo-Young T Labay E Darga TE. Glioblastoma cells block radiation-induced programmed cell death of endothelial cells. FEBS Lett. (2004 ) 565:167–70.

    Not in our library10.1016/j.febslet.2004.03.099

  236. 236.

    Nirodi CS Devalaraja R Nanney LB Arrindell S Russell S Trupin J. Chemokine and chemokine receptor expression in keloid and normal fibroblasts. Wound Repair Regen. (2000 ) 8:371–82.

    Not in our library10.1111/j.1524-475x.2000.00371.x

  237. 237.

    Russell SB Russell JD Trupin KM Gayden AE Opalenik SR Nanney LB. Epigenetically altered wound healing in keloid fibroblasts. J Invest Dermatol. (2010 ) 130:2489–96.

    Not in our library10.1038/jid.2010.162

  238. 238.

    Sharma S Kelly TK Jones PA. Epigenetics in cancer. Carcinogenesis. (2010 ) 31:27–36.

    Not in our library10.1093/carcin/bgp220

  239. 239.

    Feinberg AP Koldobskiy MA Gondor A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet. (2016 ) 17:284–99.

    Not in our library10.1038/nrg.2016.13

  240. 240.

    E Y Qipa Z Hengshu Z. The expression of DNMT1 in pathologic scar fibroblasts and the effect of 5-aza-2-deoxycytidine on cytokines of pathologic scar fibroblasts. Wounds. (2014 ) 26:139–46.

    Not in our library

  241. 241.

    Jones LR Young W Divine G Datta I Chen KM Ozog D. Genome-wide scan for methylation profiles in keloids. Dis Markers. (2015 ) 2015:943176.

    Not in our library10.1155/2015/943176

  242. 242.

    Jones LR Greene J Chen KM Divine G Chitale D Shah V. Biological significance of genome-wide DNA methylation profiles in keloids. Laryngoscope. (2017 ) 127:70–8.

    Not in our library10.1002/lary.26063

  243. 243.

    Garcia-Rodriguez L Jones L Chen KM Datta I Divine G Worsham MJ. Causal network analysis of head and neck keloid tissue identifies potential master regulators. Laryngoscope. (2016 ) 126:E319–24.

    Not in our library10.1002/lary.25958

  244. 244.

    Fitzgerald O'Connor EJ Badshah II Addae LY Kundasamy P Thanabalasingam S Abioye D Histone deacetylase 2 is upregulated in normal and keloid scars. J Invest Dermatol. (2012 ) 132:1293–6.

    Not in our library10.1038/jid.2011.432

  245. 245.

    He Y Deng Z Alghamdi M Lu L Fear MW He L. From genetics to epigenetics: new insights into keloid scarring. Cell Prolif. (2017 ) 50:e12326.

    Not in our library10.1111/cpr.12326

  246. 246.

    Totan S Echo A Yuksel E. Heat shock proteins modulate keloid formation. Eplasty. (2011 ) 11:e21.

    Not in our library

  247. 247.

    Lianos GD Alexiou GA Mangano A Rausei S Boni L Dionigi G. The role of heat shock proteins in cancer. Cancer Lett. (2015 ) 360:114–8.

    Not in our library10.1016/j.canlet.2015.02.026

  248. 248.

    Lau K Paus R Tiede S Day P Bayat A. Exploring the role of stem cells in cutaneous wound healing. Exp Dermatol. (2009 ) 18:921–33.

    Not in our library10.1111/j.1600-0625.2009.00942.x

  249. 249.

    Wang DL Zhu JJ Deng CL Wang B Yu LM. Identification of biological characteristics of human keloid-derived stem cells. Zhonghua Shao Shang Za Zhi. (2011 ) 27:210–4.

    Not in our library10.3760/cma.j.issn.1009-2587.2011.03.016

  250. 250.

    Li L Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. (2006 ) 66:4553–7.

    Not in our library10.1158/0008-5472.can-05-3986

  251. 251.

    Moon JH Kwak SS Park G Jung HY Yoon BS Park J. Isolation and characterization of multipotent human keloid-derived mesenchymal-like stem cells. Stem Cells Dev. (2008 ) 17:713–24.

    Not in our library10.1089/scd.2007.0210

  252. 252.

    Guo W Lasky JL 3rd Wu H Cancer stem cells. Pediatr Res. (2006 ) 59(4 Pt 2):59R−64R.

    Not in our library10.1203/01.pdr.0000203592.04530.06

  253. 253.

    Todaro M Alea MP Di Stefano AB Cammareri P Vermeulen L Iovino F. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. (2007 ) 1:389–402.

    Not in our library10.1016/j.stem.2007.08.001

  254. 254.

    Bao S Wu Q McLendon RE Hao Y Shi Q Hjelmeland AB. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. (2006 ) 444:756–60.

    Not in our library10.1038/nature05236

  255. 255.

    Borovski T De Sousa EMF Vermeulen L Medema JP. Cancer stem cell niche: the place to be. Cancer Res. (2011 ) 71:634–9.

    Not in our library10.1158/0008-5472.can-10-3220

  256. 256.

    Bagabir R Byers RJ Chaudhry IH Muller W Paus R Bayat A. Site-specific immunophenotyping of keloid disease demonstrates immune upregulation and the presence of lymphoid aggregates. Br J Dermatol. (2012 ) 167:1053–66.

    Not in our library10.1111/j.1365-2133.2012.11190.x

  257. 257.

    Durani P Bayat A. Levels of evidence for the treatment of keloid disease. J Plastic Reconstr Aesth Surg. (2008 ) 61:4–17.

    Not in our library10.1016/j.bjps.2007.05.007

  258. 258.

    Reish RG Eriksson E. Scars: a review of emerging and currently available therapies. Plastic Reconstr Surg. (2008 ) 122:1068–78.

    Not in our library10.1097/prs.0b013e318185d38f

  259. 259.

    Juckett G Hartman-Adams H. Management of keloids and hypertrophic scars. Am Fam Phys. (2009 ) 80:253–60.

    Not in our library

  260. 260.

    Malaker K Vijayraghavan K Hodson I Yafi TA. Retrospective analysis of treatment of unresectable keloids with primary radiation over 25 years. Clin Oncol. (2004 ) 16:290–8.

    Not in our library10.1016/j.clon.2004.03.005

  261. 261.

    Darzi MA Chowdri NA Kaul SK Khan M. Evaluation of various methods of treating keloids and hypertrophic scars: a 10-year follow-up study. Br J Plastic Surg. (1992 ) 45:374–9.

    Not in our library10.1016/0007-1226(92)90008-l

  262. 262.

    van Leeuwen MC Stokmans SC Bulstra AE Meijer OW van Leeuwen PA Niessen FB. High-dose-rate brachytherapy for the treatment of recalcitrant keloids: a unique, effective treatment protocol. Plastic Reconstr Surg. (2014 ) 134:527–34.

    Not in our library10.1097/prs.0000000000000415

  263. 263.

    Jones ME Hardy C Ridgway J. Keloid management: a retrospective case review on a new approach using surgical excision, platelet-rich plasma, and in-office superficial photon X-ray radiation therapy. Adv Skin Wound Care. (2016 ) 29:303–7.

    Not in our library10.1097/01.asw.0000482993.64811.74

  264. 264.

    Wang W Qu M Xu L Wu X Gao Z Gu T. Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways. J Mol Med. (2016 ) 94:1181–94.

    Not in our library10.1007/s00109-016-1430-3

  265. 265.

    Bijlard E Steltenpool S Niessen FB. Intralesional 5-fluorouracil in keloid treatment: a systematic review. Acta Derm Venereol. (2015 ) 95:778–82.

    Not in our library10.2340/00015555-2106

  266. 266.

    Ud-Din S Bowring A Derbyshire B Morris J Bayat A. Identification of steroid sensitive responders versus non-responders in the treatment of keloid disease. Arch Dermatol Res. (2013 ) 305:423–32.

    Not in our library10.1007/s00403-013-1328-7

  267. 267.

    De Sousa RF Chakravarty B Sharma A Parwaz MA Malik A. Efficacy of triple therapy in auricular keloids. J Cutan Aesthet Surg. (2014 ) 7:98–102.

    Not in our library10.4103/0974-2077.138347

  268. 268.

    Agbenorku P Triple keloid therapy: a combination of steroids, surgery and silicone gel strip/sheet for keloid treatment. Eur J Plast Surg. (2000 ) 23:150–1.

    Not in our library10.1007/s002380050236

  269. 269.

    Xu B Liu ZZ Zhu GY Yang JF Zhao JP Wang JC. Efficacy of recombinant adenovirus-mediated double suicide gene therapy in human keloid fibroblasts. Clin Exp Dermatol. (2008 ) 33:322–8.

    Not in our library10.1111/j.1365-2230.2007.02615.x

  270. 270.

    Ud-Din S Thomas G Morris J Bayat A. Photodynamic therapy: an innovative approach to the treatment of keloid disease evaluated using subjective and objective non-invasive tools. Arch Dermatol Res. (2013 ) 305:205–14.

    Not in our library10.1007/s00403-012-1295-4

  271. 271.

    Calzavara-Pinton PG Venturini M Sala R. Photodynamic therapy: update 2006–part 1: photochemistry and photobiology. J Eur Acad Dermatol. (2007 ) 21:293–302.

    Not in our library10.1111/j.1468-3083.2006.01902.x

  272. 272.

    Christensen E Warloe T Kroon S Funk J Helsing P Soler AM. Guidelines for practical use of MAL-PDT in non-melanoma skin cancer. J Eur Acad Dermatol Venereol. (2010 ) 24:505–12.

    Not in our library10.1111/j.1468-3083.2009.03430.x

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.